Animal Bifidobacterium lactis subspecies BAL-28 and its fermentation products, flora CW and application for preventing indigestion and flatulence and promoting absorption
By using Bifidobacterium animalis subsp. lactis BAL-28 and its fermentation products and CW microbiota, the root causes of indigestion and bloating are solved, resulting in improved intestinal function and enhanced digestion and absorption. It is suitable for various product forms.
Patent Information
- Application Number
- CN202310956580.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-08-01
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-08-01
AI Technical Summary
Existing herbal preparations, acupuncture, and enzyme preparations can only relieve symptoms of indigestion and bloating, but cannot prevent them from occurring at the root, and may also affect children's growth and development.
Using Bifidobacterium animalis subsp. lactis BAL-28 and its fermentation products and CW microbiota, a product is made to improve digestion and absorption by reducing gas production in the gastrointestinal tract, increasing probiotics, and enhancing digestive enzyme activity.
It effectively reduces gas production by intestinal flora, regulates intestinal flora balance, enhances digestive enzyme activity, promotes nutrient absorption, reduces gastrointestinal bloating, strengthens immunity, inhibits harmful bacteria, and improves vitality stability. It is suitable for various product forms.
Smart Images

Figure CN116746683B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms, and particularly relates to animal Bifidobacterium lactis subspecies BAL-28 for preventing indigestion and flatulence and promoting absorption, as well as fermentation products, flora CW and applications. Background Art
[0002] Indigestion is one of the most common diseases in internal medicine. The main symptoms are persistent or recurrent upper abdominal pain, bloating or early satiety, belching, and anorexia. Irregular diet, excessive intake of various foods, and lack of restraint can all lead to indigestion, which not only causes physical discomfort, but also seriously affects the growth and development of children.
[0003] Currently, the treatments for indigestion and bloating are mainly Chinese herbal preparations, acupuncture, and enzyme preparations, but they can usually only relieve symptoms and cannot prevent their occurrence from the root. Summary of the invention
[0004] In view of the above technical problems, the present invention provides an animal Bifidobacterium lactis subspecies BAL-28 and fermentation products, flora CW and applications thereof for preventing indigestion and flatulence and promoting absorption. The present invention has found through experimental studies that the fermentation products of the animal Bifidobacterium lactis subspecies BAL-28 strain and the fermentation products of flora CW have the effects of reducing gastrointestinal gas production, increasing the probiotic flora, and improving the activity of digestive enzymes, and can be used to make products that improve digestion and absorption.
[0005] In order to achieve the above-mentioned object of the invention, the present invention adopts the following technical solutions:
[0006] The first aspect of the present invention provides the use of animal Bifidobacterium lactis subsp. BAL-28 strain in the preparation of products that improve digestion and absorption. The strain has a preservation number of CGMCC No.7.462, and its classification name is animal Bifidobacterium lactis subsp. (Bifidobacterium animalis subsp. lactis). It was deposited in the General Microbiology Center of China National Culture Collection of Microorganisms on June 28, 2022; the preservation address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0007] Its 16S rRNA sequence is as follows:
[0008] AGTCGAACGGGATCCCTGGCAGCTTGCTGTCGGGGTGAGAGTGGCGAACGGGTGAGTAATGCGTGACCAACCTGCCCTGTGCACCGGAATAGCTCCTGGAAACGGGTGGTAATACCGGATGCTCCGCTCCATCGCATGGTGGGGTGGGAAATGCTTTTGCGGCATGGGATGGGGTCGCGTCCTATCAGCTTGTTGGCGGGGTGATGGCCCACCAAGGCGTTGACGGGTAGCCGGCCTGAGAGGGTGACCGGCCACATTGGGACTGAGATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCGACGCCGCGTGCGGGATGGAGGCCTTCGGGTTGTAAACCGCTTTTGTTCAAGGGCAAGGCACGGTTTCGGCCGTGTTGAGTGGATTGTTCGAATAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCGAGCGTTATCCGGATTTATTGGGCGTAAAGGGCTCGTAGGCGGTTCGTCGCGTCCGGTGTGAAAGTCCATCGCCTAACGGTGGATCTGCGCCGGGTACGGGCGGGCTGGAGTGCGGTAGGGGAGACTGGAATTCCCGGTGTAACGGTGGAATGTGTAGATATCGGGAAGAACACCAATGGCGAAGGCAGGTCTCTGGGCCGTCACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGATGCTGGATGTGGGGCCCTTTCCACGGGTCCCGTGTCGGAGCCAACGCGTTAAGCATCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGAAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGCGGATTAATTCGATGCAACGCGAAGAACCTTACCTGGGCTTGACATGTGCCGGATCGCCGTGGAGACACGGTTTCCCTTCGGGGCCGGTTCACAGGTGGTGCATGGTCGTCGTCAGCTCGTGTCGTGAGAT GTTGGGTTAAGTCCCGCAACGAGCGCAACCCTCGCCGCATGTTGCCAGCGGGTGATGCCGGGAACTCATGTGGGACCGCCGGGGTCAACTCGGAGGAAGGTGGGGATGACGTCAGATCATCATGCCCCT TACGTCCAGGGCTTCACGCATGCTACAATGGCCGGTACAACGCGGTGCGACACGGTGACGTGGGGCCGGATCGCTGAAAACCGGTCTCAGTTCGGATCGCAGTCTGCAACTCGACTGCGTGAAGGCGGA GTCGCTAGTAATCGCGGATCAGCAACGCCGCGGTGAATGCGTTCCCGGGCCTTGTACACACCGCCCGTCAAGTCATGAAAGTGGGTAGCACCCGAAGCCGGTGGCCCGACCCTTGTGGGGGGAGCCGT.
[0009] The animal Bifidobacterium lactis subspecies BAL-28 strain has been disclosed in a patent with application number CN202310645330.5 and titled "A strain of Lactobacillus rhamnosus LR-28 with calming and sleep-inducing effects, fermentation products, sleeping flora combination agents and applications".
[0010] Compared with the prior art, the animal Bifidobacterium lactis subspecies BAL-28 with a deposit number of CGMCC No.7.462 provided by the present invention has the following advantages in improving digestion and absorption:
[0011] (1) It can reduce the gas production of intestinal flora, thereby improving gastrointestinal bloating symptoms;
[0012] (2) It can increase the number of beneficial bacteria in the intestines and regulate the balance of intestinal flora. On the one hand, it can maintain a healthy gastrointestinal flora, which is beneficial to improving the body's digestive and absorption functions. On the other hand, the increase in the number of probiotics can also help improve the body's immunity.
[0013] (3) It can increase the activity of digestive enzymes such as amylase, protease and lipase produced by intestinal flora, thereby promoting the digestion of starch, protein and fat in food, making nutrients easier to absorb. In addition, digestive enzymes can also promote gastrointestinal motility to a certain extent and improve intestinal function.
[0014] (4) It has very high acid resistance and bile salt resistance, and can resist the characteristics of artificial gastric juice and artificial intestinal juice, ensuring that it can survive in large quantities and colonize in the intestine after being digested by the stomach and intestine; it can more effectively adhere to the intestinal mucosa, form a biological barrier, and protect the intestine; it has high antibacterial activity, can effectively inhibit or kill Escherichia coli and Helicobacter pylori, and then alleviate the symptoms of gastritis, secretory diarrhea, electrolyte disorders, and acidosis caused by endotoxins secreted by Escherichia coli and Helicobacter pylori, reduce the damage of endotoxins to the intestinal mucosa, and improve intestinal function. The above effects help to further improve the effect of animal Bifidobacterium lactis subspecies BAL-28 in improving digestion and absorption.
[0015] (5) It has excellent activity stability and is easy to maintain its original activity during product processing, production, transportation and storage. It does not require the control of harsh processing, transportation and storage conditions, and it is easier to obtain a longer shelf life, which is conducive to practical application.
[0016] In combination with the first aspect, the product is a product for reducing flatulence.
[0017] In combination with the first aspect, the product is a product that promotes digestion.
[0018] In combination with the first aspect, the product is a product for improving intestinal function.
[0019] In combination with the first aspect, the products include bacterial preparations, health products, formula milk powder, solid beverages and functional foods, but do not include infant food.
[0020] In a second aspect, the present invention also provides the use of the fermentation product of the above-mentioned Bifidobacterium animalis subsp. lactis BAL-28 strain in the preparation of a product that improves digestion and absorption.
[0021] Experimental studies have found that the fermentation products of the animal Bifidobacterium lactis subspecies BAL-28 strain can reduce flatulence, regulate gastrointestinal flora, and promote the secretion of digestive enzymes, and can therefore be made into products that improve digestion and absorption.
[0022] In combination with the second aspect, the fermentation product is fermentation bacterial sludge or fermentation bacterial suspension.
[0023] Preferably, the method for preparing the fermentation product comprises the following operations: culturing the seed liquid of animal Bifidobacterium lactis subsp. lactis BAL-28 strain in a modified MRS liquid medium, and fermenting at least once, more preferably three times in a row.
[0024] In conjunction with the second aspect, the product is a product for reducing flatulence.
[0025] In conjunction with the second aspect, the product is a product that promotes digestion.
[0026] In combination with the second aspect, the product is a product for improving intestinal function.
[0027] In combination with the second aspect, the products include bacterial preparations, health products, formula milk powder, solid beverages and functional foods, but do not include infant food.
[0028] In a third aspect, the present invention also provides a flora CW, comprising the above-mentioned animal Bifidobacterium lactis subspecies BAL-28 strain, as well as Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28, wherein the classification name of the Lactobacillus plantarum LP-28 is Lactobacillus plantarum, and the preservation number is CGMCC No.7.463, and the classification name of the Lactobacillus rhamnosus LR-28 is Lactobacillus rhamnosus, and the preservation number is CGMCC No.7.464.
[0029] Experimental studies have found that the fermentation products of the bacterial community CW composed of animal Bifidobacterium lactis subspecies BAL-28, Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28 can more effectively reduce flatulence, regulate gastrointestinal flora, promote the secretion of digestive enzymes, and can be made into products that are more effective in improving digestion and absorption.
[0030] Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28 have been disclosed in a patent with application number CN202310645330.5 and titled "A strain of Lactobacillus rhamnosus LR-28 with calming and sleep-inducing effects, fermentation products, sleeping bacteria combination preparations and applications".
[0031] In a fourth aspect, the present invention further provides the use of the above-mentioned flora CW in the preparation of a bacterial agent for improving digestion and absorption, wherein the active ingredient in the bacterial agent includes a fermentation product of the above-mentioned flora CW.
[0032] In combination with the fourth aspect, the fermentation product is fermentation bacterial sludge or fermentation bacterial suspension.
[0033] Preferably, the method for preparing the fermentation product comprises the following operations: culturing the seed solution of Bifidobacterium animalis subsp. lactis BAL-28, the seed solution of Lactobacillus plantarum LP-28 and the seed solution of Lactobacillus rhamnosus LR-28 in a modified MRS liquid medium, respectively, fermenting at least once, and mixing the fermentation products. More preferably, the fermentation is performed three times in a row.
[0034] Preferably, the method for preparing the fermentation product further comprises mixing the fermentation products and fermenting them again in a modified MRS liquid culture medium at least once.
[0035] Optionally, the seed culture conditions are: inoculation amount 3%, and culture at 37° C. for 24 hours.
[0036] Preferably, the fermentation products of the respective bacteria are mixed in a ratio of 3:(0.8-1.2):(0.8-1.2) in terms of viable bacteria count. A more preferred ratio of 3:1:1 in terms of viable bacteria count is preferred.
[0037] In combination with the fourth aspect, the bacterial agent is a product for reducing flatulence.
[0038] In combination with the fourth aspect, the product is a product that promotes digestion.
[0039] In combination with the fourth aspect, the product is a product for improving intestinal function.
[0040] In conjunction with the fourth aspect, the products include health products, formula milk powder, solid beverages and functional foods, but do not include infant food. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 The acid resistance test results of animal Bifidobacterium lactis subspecies BAL-28 and commonly used commercial animal Bifidobacterium lactis subspecies Bb-12 in Example 3;
[0042] Figure 2 The bile salt resistance test results of animal Bifidobacterium lactis subspecies BAL-28 and commonly used commercial animal Bifidobacterium lactis subspecies Bb-12 in Example 3;
[0043] Figure 3 The adhesion test results of animal Bifidobacterium lactis subspecies BAL-28 and commonly used commercial animal Bifidobacterium lactis subspecies Bb-12 in Example 3;
[0044] Figure 4 These are the antibacterial test results of the animal Bifidobacterium lactis subspecies BAL-28 and the commonly used commercial animal Bifidobacterium lactis subspecies Bb-12 in Example 3. DETAILED DESCRIPTION
[0045] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0046] The strains used in the following examples of the present invention are derived from the following:
[0047] Lactobacillus plantarum LP-28, whose classification name is Lactobacillus plantarum (Lactobacillus plantarum), was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on June 25, 2022, and its deposit number is CGMCC No.7.463; the deposit address is No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing.
[0048] Lactobacillus rhamnosus LR-28, whose classification name is Lactobacillus rhamnosus (Lactobacillus rhamnosus), was deposited in the General Microbiology Center of China Microorganism Culture Collection on June 26, 2022, and its deposit number is CGMCC No.7.464; the deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0049] Commonly used commercial animal Bifidobacterium lactis subspecies Bb-12 strain, Escherichia coli (strain number ATCC 25922), and Helicobacter pylori (ss1 strain).
[0050] Intestinal flora proliferation medium: Each liter of culture medium contains 1g casein hydrolysate, 1g yeast extract, 2g K2HPO4, 3.2g NaHCO3, 4.5g NaCl, 0.5g MgSO4.7H2O, 0.4g CaCl2·2H2O, 0.005g FeSO4.7H2O, 0.01g heme, 0.05g bile salt, 0.6ml barium sulfate (0.1%), 0.5g cysteine HCl, 3.6ml volatile fatty acid (VFA) solution (each 40ml contains 17ml acetic acid, 1ml n-valeric acid, 1ml isovaleric acid and 1ml isobutyric acid), 20ml NaOH (10mM), 2ml mineral solution (each L contains 500mg EDTA, 200mg FeSO4.7H2O, 10mg ZnSO4.7H2O, 3mg MnCl2.7H2O, 30mg H3BO3, 20mg CoCl2.6H2O, 1mg CuCl2.2H2O, 2mg NiCl2.6H2O, 3mg NaMoO4.2H2O, 7.5mgNaSeO3), 1.4ml vitamin solution (1g menadione, 2g biotin, 2g pantothenate, 10g nicotinamide, 0.5g cobalamin, 4g thiamine, 5g p-aminobenzoic acid per L; filter sterilized). Cysteine is added to the medium after boiling and dispensed into a wire-mouth bottle while flushing with CO2. The vitamin solution is added after the medium is autoclaved and before inoculation with the intestinal flora suspension.
[0051] In vitro fermentation system of intestinal flora: take fresh human feces and add 10 times the volume of anaerobic PBS buffer in an anaerobic operating table. After mixing at 4°C, filter to remove the residue to obtain an intestinal flora suspension. Inoculate 10 ml of the intestinal flora suspension into 100 ml of intestinal flora proliferation culture medium to obtain an intestinal flora in vitro fermentation system.
[0052] Modified MRS liquid medium: Each liter of culture medium contains 9.0 g peptone, 9.5 g beef powder, 4.0 g yeast powder, 17.5 g glucose, 0.09 g magnesium sulfate, 1.9 g sodium acetate, 4.5 g ammonium citrate, 1.8 g dipotassium hydrogen phosphate, 0.04 g manganese sulfate, 0.9 g Tween 80, and 0.06 g L-cysteine hydrochloride (pH 6.2±0.2).
[0053] Unless otherwise specified, other experimental materials and instruments can be purchased through commercial channels.
[0054] Example 1
[0055] This embodiment provides a fermentation bacterial suspension of Bifidobacterium animalis subsp. lactis BAL-28 strain.
[0056] Its preparation method is:
[0057] The seed liquid of animal Bifidobacterium lactis subsp. lactis BAL-28 was inoculated into the modified MRS liquid culture medium at an inoculation rate of 3%, shaken and mixed, cultured at 37° C. for 24 hours, and fermented three times continuously according to the fermentation parameters to obtain the fermentation bacterial suspension.
[0058] Example 2
[0059] This embodiment provides a bacterial suspension obtained by CW fermentation of a bacterial community consisting of Bifidobacterium animalis subsp. lactis BAL-28 strain, Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28.
[0060] Its preparation method is:
[0061] The seed liquid of animal Bifidobacterium lactis subspecies BAL-28, the seed liquid of Lactobacillus plantarum LP-28 and the seed liquid of Lactobacillus rhamnosus LR-28 are inoculated into the improved MRS liquid culture medium at an inoculation amount of 3%, respectively, shaken and mixed, cultured at 37°C for 24 hours, and fermented three times continuously according to the fermentation parameters, and the obtained fermentation liquids are mixed according to the live cell count ratio of animal Bifidobacterium lactis subspecies BAL-28: Lactobacillus plantarum LP-28: Lactobacillus rhamnosus LR-28=3:1:1, inoculated into the improved MRS liquid culture medium at an inoculation amount of 3%, shaken and mixed, and cultured at 37°C for 24 hours to obtain the fermentation bacterial suspension.
[0062] Example 3
[0063] This example provides the probiotic properties of the fermented bacteria suspension of Example 1 and its effect on improving digestion and absorption.
[0064] 1. Gastric acid resistance and bile salt resistance test
[0065] 1.1 Acid resistance test
[0066] The fermentation bacterial suspension of animal Bifidobacterium lactis subspecies BAL-28 of Example 1 and the fermentation bacterial suspension of commonly used commercial animal Bifidobacterium lactis subspecies Bb-12 strain (fermented according to the preparation method of Example 1) were inoculated at a 2% inoculum into MRS liquid culture medium with a pH value of 3.0, cultured in an incubator at 37°C, and the number of viable cells at 0 and 4h was determined (plate count method). The results are shown in Figure 1 .
[0067] 1.2 Bile salt tolerance test: The activated animal Bifidobacterium lactis subspecies BAL-28 strain screened in Example 1 and the commonly used commercial animal Bifidobacterium lactis subspecies Bb-12 strain were inoculated into MRS liquid culture medium containing 0.03% ox bile salt, placed in a 37°C incubator for culture, and the number of viable bacteria at 0h and 4h was measured (plate count method). The results are shown in Figure 2 .
[0068] The results show that compared with commonly used commercial strains of the same species, the animal Bifidobacterium lactis subspecies BAL-28 strain has very high acid and bile salt resistance, and can resist the characteristics of artificial gastric juice and artificial intestinal juice, ensuring that it can survive in large numbers and colonize in the intestine after digestion in the stomach and intestines.
[0069] 2. Adhesion test
[0070] The caco-2 cells were inoculated into a 12-well plate at a concentration of 1×10 cells / mL and cultured at 37°C under 5% CO2 until a monolayer of cells was formed. The culture medium was discarded, and the cells were gently washed three times with sterile PBS buffer. 1 mL of DMEM stock solution was added, and then the fermentation bacterial suspension of animal Bifidobacterium lactis subsp. BAL-28 strain and the commonly used commercial animal Bifidobacterium lactis subsp. Bb-12 strain (suspended in DMEM, with a concentration of about 10 10 cfu / mL), three wells were made for each bacterial strain, and after culturing for 2 hours, the supernatant was discarded, and the cells were washed three times with sterile PBS. 300 μL of 0.25% trypsin was added to each well for digestion for 5-8 minutes, and then 300 μL of incomplete DMEM medium (containing serum but not double antibody) was added to terminate the digestion, and then the dilution was spread on the plate to calculate the number of adherent strains.
[0071] Adhesion rate (%) = number of adherent strains / initial inoculation number × 100%.
[0072] Results Figure 3Compared with the commonly used commercial animal Bifidobacterium lactis subspecies Bb-12, animal Bifidobacterium lactis subspecies BAL-28 can more effectively adhere to the intestinal mucosa, form a biological barrier, protect the intestines, and provide an important prerequisite for colonization in the human intestine.
[0073] 3. Antibacterial test
[0074] The fermentation bacterial suspension of animal Bifidobacterium lactis subsp. BAL-28 of Example 1 and the fermentation bacterial suspension of commonly used commercial animal Bifidobacterium lactis subsp. Bb-12 strain (fermented according to the preparation method of Example 1) were inoculated into a 2 mL EP tube containing MRS liquid culture medium at an inoculation rate of 2%, and placed in a 37° C. constant temperature incubator for 18 h. The above-mentioned animal Bifidobacterium lactis subsp. BAL-28 culture solution was centrifuged at 500 g for 10 min to obtain the supernatant for use.
[0075] Escherichia coli (ATCC 25922) and Helicobacter pylori (ss1 strain) were used as indicator bacteria. Take 100 μL of activated indicator bacteria and adjust the concentration of indicator bacteria to 1.0×10 5 CFU / mL, plate the corresponding culture medium, place the culture dish on a semi-open clean bench for 10 minutes, add 200 μL of animal Bifidobacterium lactis subsp. lactis BAL-28 supernatant to the Oxford cup with solid culture medium, and culture it steadily at 37°C for 16 hours. Observe and measure the diameter of the inhibition zone of each bacterial solution, and perform three groups of experiments in parallel.
[0076] The results are shown in Figure 4 Compared with the commonly used commercial Bifidobacterium lactis subspecies Bb-12, animal Bifidobacterium lactis subspecies BAL-28 can more effectively inhibit Escherichia coli and Helicobacter pylori.
[0077] 4. Vitality stability test
[0078] Animal Bifidobacterium lactis subspecies BAL-28 powder has excellent vitality stability. Animal Bifidobacterium lactis subspecies BAL-28 seed liquid is inoculated into the modified MRS liquid medium at an inoculum amount of 3%, shaken and mixed, cultured at 37°C for 24h, and fermented three times continuously according to the fermentation parameters. The fermentation liquid obtained by the third fermentation is centrifuged at 6000r / min for 30min to obtain bacterial mud, the bacterial mud is mixed evenly with the freeze-drying protective agent, and then freeze-dried, and then crushed to obtain animal Bifidobacterium lactis subspecies BAL-28 powder. The bacterial powder is stored at -18°C, 25°C, and 30°C constant temperature conditions to observe the decay of its viable count. Detailed data are shown in Table 1.
[0079] Table 1 Viable bacteria survival rate
[0080]
[0081] 5. Improve digestion and absorption test
[0082] 5.1 Test process
[0083] 10 ml of modified MRS was inoculated into 110 ml of intestinal flora in vitro fermentation system as a blank control; 10 ml of fermentation suspension of animal Bifidobacterium lactis subspecies BAL-28 of Example 1 was inoculated into 110 ml of intestinal flora in vitro fermentation system. After anaerobic culture at 37°C for 24 hours, the gas production of each bottle was detected by a handheld gas pressure measuring instrument. After the determination was completed, 1 ml of the fermented liquid in the container was taken to detect the content of bifidobacteria and lactobacilli by qPCR.
[0084] The fermentation liquid in the container was centrifuged at 13000 rpm for 3 min, and the supernatant was filtered to determine the digestive enzyme activity, wherein the amylase activity, protease activity and lipase activity were determined using an amylase activity detection kit (Merck MAK009), a protease detection kit (fluorescence method) (Merck PF0100), and a lipase activity detection kit III (Merck MAK048), respectively. The operation method followed the instructions for use of the kit.
[0085] 5.2 Test results
[0086] The gas production results are shown in Table 2.
[0087] Table 2 Gas production
[0088] Group Gas output (kPa) Blank control (MRS medium) 15.2 Example 1 (BAL-28 fermentation bacteria suspension) 11.9
[0089] It can be seen that Bifidobacterium animalis subsp. lactis BAL-28 can reduce the amount of gas produced in the system, indicating that this strain can reduce the gas production of intestinal flora and has the potential to reduce gastrointestinal flatulence.
[0090] The changes in the contents of Bifidobacterium and Lactobacillus are shown in Table 3.
[0091] Table 3 Bifidobacterium and Lactobacillus content
[0092] Group Bifidobacterium Lactobacillus Blank control (MRS medium) <![CDATA[1.37×10 11 ]]> <![CDATA[7.38×10 11 ]]> Example 1 (BAL-28 fermentation bacteria suspension) <![CDATA[2.69×10 12 ]]> <![CDATA[1.13×10 12 ]]>
[0093] It can be seen that animal Bifidobacterium lactis subspecies BAL-28 can proliferate the number of bifidobacteria and lactobacilli in the intestine, indicating that this strain can increase the beneficial bacteria in the intestine and regulate the balance of intestinal flora.
[0094] The changes in digestive enzyme activities are shown in Table 4
[0095] Table 4 Digestive enzyme activity
[0096]
[0097] It can be seen that animal Bifidobacterium lactis subspecies BAL-28 can enhance the production of amylase, protease and lipase activities by intestinal flora, indicating that this strain can promote the digestion and absorption of nutrients.
[0098] Example 4
[0099] This example provides the effect of the fermentation bacteria suspension of Example 2 in improving digestion and absorption.
[0100] 1. Test process
[0101] The blank control is the same as in Example 3; three intestinal flora in vitro fermentation systems are taken separately, each with 10 ml, one is inoculated with 10 ml of the flora CW fermentation bacterial suspension of Example 2 (the ratio of the number of live bacteria of animal Bifidobacterium lactis subspecies BAL-28, Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28 is 3:1:1), one is inoculated with 10 ml of Lactobacillus plantarum LP-28 fermentation bacterial suspension (preparation method is the same as in Example 1), and one is inoculated with 10 ml of Lactobacillus rhamnosus LR-28 fermentation bacterial suspension (preparation method is the same as in Example 1). After anaerobic culture at 37 ° C for 24 hours, a handheld barometer is used to detect the gas production of each bottle. After the determination is completed, 1 ml of the fermented liquid in the container is taken to detect the content of bifidobacteria and lactobacilli by qPCR.
[0102] The fermentation liquid in the container was centrifuged at 13000 rpm for 3 min, and the supernatant was filtered to determine the digestive enzyme activity. The amylase activity, protease activity and lipase activity were determined using an amylase activity detection kit (Merck MAK009), a protease detection kit (fluorescence method) (Merck PF0100), and a lipase activity detection kit III (Merck MAK048), respectively. The operation method followed the instructions for use of the kit.
[0103] 2. Test results
[0104] The gas production results are shown in Table 5.
[0105] Table 5 Gas production
[0106] Group Gas output (kPa) Blank control (MRS medium) 15.2 Example 2 Bacteria CW (BAL-28 + LP-28 + LR-28) fermentation bacterial suspension 10.9 LP-28 fermentation bacteria suspension 12.7 LR-28 fermentation bacteria suspension 13.6
[0107] It can be seen that Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28 can also reduce the amount of gas produced in the system, but the fermentation bacterial suspension of flora CW (BAL-28+LP-28+LR-28) has a better effect on reducing gas production, and the gas production is significantly lower than that of each strain inoculated alone, indicating that animal Bifidobacterium lactis subspecies BAL-28, Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28 have a synergistic effect in reducing gas production, can more effectively reduce the gas production of intestinal flora, and have greater potential in reducing gastrointestinal flatulence.
[0108] The changes in the contents of Bifidobacterium and Lactobacillus are shown in Table 6.
[0109] Table 6 Bifidobacterium and Lactobacillus content
[0110] Group Bifidobacterium Lactobacillus Blank control (MRS medium) <![CDATA[1.37×10 11 ]]> <![CDATA[7.38×10 11 ]]> Example 2 Bacteria CW (BAL-28 + LP-28 + LR-28) fermentation bacterial suspension <![CDATA[2.86×10 12 ]]> <![CDATA[2.39×10 12 ]]> LP-28 fermentation bacteria suspension <![CDATA[2.45×10 11 ]]> <![CDATA[2.14×10 12 ]]> LR-28 fermentation bacteria suspension <![CDATA[1.96×10 11 ]]> <![CDATA[1.45×10 12 ]]>
[0111] It can be seen that Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28 can also proliferate the number of bifidobacteria and lactobacilli in the intestine, but the fermented bacterial suspension of flora CW (BAL-28+LP-28+LR-28) has a more significant effect on proliferating the number of bifidobacteria and lactobacilli in the intestine. The increase in the number of bifidobacteria and lactobacilli is significantly higher than that of using each strain alone, indicating that animal Bifidobacterium lactis subspecies BAL-28, Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28 also have a synergistic effect on the number of bifidobacteria and lactobacilli, and can more significantly increase the beneficial bacteria in the intestine and regulate the balance of intestinal flora.
[0112] The changes in digestive enzyme activity are shown in Table 7
[0113] Table 7 Digestive enzyme activity
[0114]
[0115] It can be seen that Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28 can also enhance the production of amylase, protease and lipase activities by intestinal flora, but the fermented bacterial suspension of flora CW (BAL-28+LP-28+LR-28) has a more obvious effect on improving enzyme activity, which is significantly better than inoculating each strain alone. This shows that animal Bifidobacterium lactis subspecies BAL-28, Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28 also have a synergistic effect in improving the activity of digestive enzymes, and can more effectively promote the digestion and absorption of nutrients.
[0116] Example 5
[0117] This embodiment provides a probiotic preparation for improving digestion, wherein the probiotic preparation is fermented by Bifidobacterium animalis subsp. lactis BAL-28 strain.
[0118] The preparation method of the bacterial agent is as follows:
[0119] The seed liquid of animal Bifidobacterium lactis subsp. lactis BAL-28 was inoculated into the modified MRS liquid medium at an inoculum volume of 3%, and the mixture was shaken and mixed, and cultured at 37°C for 24 h. The fermentation was repeated three times according to the fermentation parameters. The fermentation liquid obtained by the third fermentation was centrifuged at 6000 r / min for 30 min to obtain bacterial sludge. The bacterial sludge was mixed evenly with a freeze-drying protective agent, freeze-dried, and then crushed. According to the actual production bacterial count, maltodextrin was used as a filling diluent for mixing to obtain the final probiotic product for improving digestion (the number of viable bacteria was 1.0×10 10 CFU / g).
[0120] Preparation method of freeze-dried protective agent: 100g starch, 20g glucose, 60g maltodextrin, 30g sucrose, 10g lactose, 50g skimmed milk powder and other food raw materials are mixed evenly, 1000g pure water is added to dissolve until no particles are visible to the naked eye, the pH is adjusted to 5.0-6.8 after the materials are dissolved, and sterilized at 117.5-118.5℃ for 20min. After sterilization, the pH is adjusted to 6.0-7.3 to obtain the freeze-dried protective agent.
[0121] Example 6
[0122] This embodiment provides a CW composite probiotic preparation for improving digestion, which is obtained by fermenting CW (Bifidobacterium animalis subsp. lactis BAL-28 strain, Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28).
[0123] The preparation method of the bacterial agent is as follows:
[0124] The seed liquid of animal Bifidobacterium lactis subspecies BAL-28, Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28 were inoculated into the modified MRS liquid medium at an inoculation rate of 3%, shaken and mixed, cultured at 37°C for 24 hours, and fermented three times continuously according to the fermentation parameters. The fermentation liquid obtained by the third fermentation was centrifuged at 6000r / min for 30 minutes to obtain bacterial mud, and then mixed with the freeze-drying protective agent and freeze-dried, and then crushed. The crushed bacterial powder was mixed at a live bacterial count ratio of 3:1:1 to obtain a composite bacterial agent for improving digestion (live bacterial count of 1.0×10 10 CFU / g).
[0125] Preparation method of freeze-dried protective agent: 100g starch, 20g glucose, 60g maltodextrin, 30g sucrose, 10g lactose, 50g skimmed milk powder and other food raw materials are mixed evenly, 1000g pure water is added to dissolve until no particles are visible to the naked eye, the pH is adjusted to 5.0-6.8 after the materials are dissolved, and sterilized at 117.5-118.5℃ for 20min. After sterilization, the pH is adjusted to 6.0-7.3 to obtain the freeze-dried protective agent.
[0126] Example 7
[0127] This example provides the application effect of the bacterial agents of Example 5 and Example 6 in improving digestion and absorption in children.
[0128] According to the diagnostic criteria of functional dyspepsia in children, 100 children over 3 years old who meet the symptoms were recruited, and the legal guardians were informed and agreed. The above children were grouped: the control group took maltodextrin (2g / bar) every day, the probiotic preparation (2g / bar, the preparation method is the same as in Example 5) made by Lactobacillus plantarum LP-28 was taken in test group 1, the probiotic preparation (2g / bar, the preparation method is the same as in Example 5) made by Lactobacillus rhamnosus LR-28 was taken in test group 2, the probiotic preparation (2g / bar, the preparation method is the same as in Example 5) made by Bifidobacterium lactis subspecies BAL-28 was taken in test group 3 (i.e., Example 5, 2g / bar), and the flora CW composite probiotic preparation (i.e., Example 6, 2g / bar) made by Bifidobacterium lactis subspecies BAL-28, Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28 was taken in test group 4. Take 1 time after meals every day, 1 bar each time. Compare the symptom disappearance time of each group. The results are shown in Table 8.
[0129] Table 8 The time of disappearance of clinical symptoms in each group of children (X, d)
[0130]
[0131] Compared with the control group, the experimental groups 1, 2, 3 and 4 had excellent effects in relieving children's indigestion and promoting the relief of indigestion symptoms, especially in relieving loss of appetite, abdominal distension and nausea, and had a relieving effect on acid reflux and belching, but there was no significant difference compared with the control group; the effects of experimental groups 3 and 4 were better than those of experimental groups 1 and 2, and experimental group 4 was better than the single strain at the same dose in relieving abdominal distension and nausea. The results show that animal Bifidobacterium lactis subspecies BAL-28, Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28 have the effect of relieving indigestion, and animal Bifidobacterium lactis subspecies BAL-28 has a better effect and there is a synergistic effect between the three strains. The bacterial community CW composite bacterial agent made from these three strains has the best effect.
[0132] Example 8
[0133] This example provides the application effect of the bacterial agents of Example 5 and Example 6 in improving digestion and absorption in adults.
[0134] According to the diagnostic criteria for functional dyspepsia in healthy Chinese adults in the 2015 Consensus on Functional Dyspepsia (FD), 100 adults aged 15-75 years and above who met the symptoms were recruited. The adults were divided into the following groups:
[0135] Control group takes maltodextrin (2g / bar) every day, test group 1 takes the probiotic preparation (2g / bar, preparation method is with embodiment 5) that lactobacillus plantarum LP-28 makes, test group 2 takes the probiotic preparation (2g / bar, preparation method is with embodiment 5) that lactobacillus rhamnosus LR-28 makes, test group 3 takes the probiotic preparation (i.e. embodiment 5, 2g / bar) that animal bifidobacterium lactis subspecies BAL-28 makes, test group 4 takes the flora CW composite probiotic preparation (i.e. embodiment 6, 2g / bar) that animal bifidobacterium lactis subspecies BAL-28, lactobacillus plantarum LP-28 and lactobacillus rhamnosus LR-28 make. Take 1 time after meal every day, 1 bar each time. Relatively organize symptom disappearance time. The results are shown in Table 9.
[0136] Table 9 Time of disappearance of clinical symptoms in each group of adults (X, d)
[0137]
[0138] Compared with the control group, the experimental groups 1, 2, 3 and 4 also had excellent effects in relieving functional dyspepsia in adults and promoting the relief of dyspepsia symptoms, especially in relieving loss of appetite and relieving abdominal distension and nausea. There were significant differences, and there was a relieving effect on acid reflux and belching, but there was no significant difference compared with the control group; the effects of experimental groups 3 and 4 were significantly better than those of experimental groups 1 and 2, and experimental group 4 was better than the use of a single strain in relieving abdominal distension, nausea and acid reflux and belching. The results show that animal Bifidobacterium lactis subspecies BAL-28, Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28 have the effect of relieving dyspepsia, and animal Bifidobacterium lactis subspecies BAL-28 has a better effect and there is a synergistic effect between the three strains. The bacterial community CW composite bacterial agent made from these three strains has the best effect.
[0139] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. An application of bacterial flora CW in the preparation of a bacterial agent for reducing flatulence, characterized in that: The bacterial flora CW includes Bifidobacterium animalis subspecies lactis BAL-28, as well as Lactobacillus plantarum LP-28 and Lactobacillus rhamnosus LR-28; Wherein, the classification name of the animal Bifidobacterium lactis subspecies BAL-28 is animal Bifidobacterium lactis subspecies ( Bifidobacterium animalis subsp. lactis ), the deposit number is CGMCC No.7.462; The classification name of the plant lactobacillus LP-28 is plant lactobacillus ( Lactobacillus plantarum ), the deposit number is CGMCC No.7.463; The classification name of the Lactobacillus rhamnosus LR-28 is Lactobacillus rhamnosus ( Lactobacillus rhamnosus ), the deposit number is CGMCC No.7.464; The active ingredients in the bacterial agent include the fermentation products of the bacterial community CW.
2. The use according to claim 1, characterized in that: The method for preparing the fermentation product comprises the following operations: carrying out seed culture of the seed liquid of each strain in a modified MRS liquid medium, fermenting at least once, and mixing the fermentation products to obtain the product.
3. The use according to claim 1 or 2, characterized in that: The bacterial agent also has the effect of promoting digestion and / or improving intestinal function.
4. The use according to claim 1 or 2, characterized in that: The bacterial agent is a formula milk powder, a solid beverage or a functional food including a health product, but does not include infant food.
Citation Information
Patent Citations
Probiotics for use in relieving symptoms associated with gastrointestinal disorders
CN101998834A
Heat-resistant bifidobacterium animalis subsp.lactis separated from feces of baby
CN110577919A
Bifidobacterium animal subspecies lactis JMCC0025 and isolation and purification method and application of JMCC0025
CN110923166A
Bifidobacterium animalis subsp. Lactis i797, purification method and application thereof
CN111484957A
Application of bifidobacterium animalis subsp. Lactis i797 capable of improving infantile diarrhea and dyspepsia
CN111543640A
Cited By
Lactobacillus paracasei YM2024 for degrading pesticide residues, fermentation product, flora YM-Clean and application
CN119752734A
A strain of Lactobacillus paracasei YM2024 for degrading pesticide residues, its fermentation product, bacterial flora YM-Clean and applications
CN119752734B
Streptococcus salivarius subsp. thermophilus YM1921, YM1921-TWK10 flora and metabolites and metachion for promoting bone development, improving bone density and reducing cartilage wear
CN122979153A
